Corcept Therapeutics (CORT) vs Elanco Animal Health (ELAN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Corcept Therapeutics (CORT) has outperformed Elanco Animal Health (ELAN) over the past year, gaining 32.4% versus a gain of 9.3%. Over five years, CORT leads with a +496.8% price change compared with -31.3% for ELAN. Corcept Therapeutics is the larger company by market cap ($12.84 billion vs $11.24 billion), about 1.1 times the size.
On valuation, Elanco Animal Health trades at a lower forward P/E (17.5x vs 27.0x for Corcept Therapeutics). Corcept Therapeutics converts more of its revenue into profit, with a net margin of 13.1% versus -4.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CORT | ELAN |
|---|---|---|
| Share price | $118.78 | $22.50 |
| Market cap | $12.84B | $11.24B |
| 1-day change | -0.69% | +0.63% |
| YTD return | +243.68% | -1.19% |
| 1-year return | +32.42% | +9.34% |
| 5-year return | +496.81% | -31.28% |
| P/E ratio (TTM) | 263.96 | — |
| Forward P/E | 26.98 | 17.51 |
| EPS (TTM) | $0.45 | $-0.41 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $761.41M | $4.71B |
| Revenue growth (YoY) | +12.79% | +6.22% |
| Net income (latest FY) | $99.65M | $-232.00M |
| Gross margin | 98.30% | 54.99% |
| Operating margin | 5.88% | — |
| Net margin | 13.09% | -4.92% |
| 52-week high | $126.38 | $27.98 |
| 52-week low | $28.66 | $19.40 |
| Distance from 52-week high | -6.01% | -19.59% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +18.71% | +37.78% |
| Average volume | 1.30M | 6.18M |
| Shares outstanding | 108.10M | 499.45M |
| Employees | 730 | 9,400 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CORT has outperformed ELAN by 23.1 percentage points over the past year.
- Corcept Therapeutics is more profitable, keeping 13.1 cents of every revenue dollar as net income versus -4.9 cents for Elanco Animal Health.
- Corcept Therapeutics grew revenue faster in its latest fiscal year (+12.79% vs +6.22%).
About Corcept Therapeutics
CORT stock →Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.
Health Care · Biotechnology: Pharmaceutical Preparations · 730 employees
About Elanco Animal Health
ELAN stock →Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal family, and Drontal Plus; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark.
Health Care · Biotechnology: Pharmaceutical Preparations · 9,400 employees
CORT vs ELAN FAQ
Which is bigger, Corcept Therapeutics or Elanco Animal Health?
Corcept Therapeutics (CORT) is larger, with a market capitalization of $12.84B compared with $11.24B for Elanco Animal Health (ELAN).
Which stock has performed better over the past year, CORT or ELAN?
CORT returned +32.42% over the past 12 months, compared with +9.34% for ELAN (price return, excluding dividends). Past performance does not predict future results.
Are Corcept Therapeutics and Elanco Animal Health in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.